Title: Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities Name: 2018 Norwegian Cohort Study Official title (coded as: official from http://hl7.org/fhir/title-type): The Long-Term Effect of Treatment of Morbid Obesity Acronym (coded as: acronym from http://hl7.org/fhir/title-type); LETMO: Short title (coded as: short-title from http://hl7.org/fhir/title-type): LETMO - a cohort study Identifier: FOI 208285 Identifier: REK project number identifier 2010/2329 Study start and end: July 2010 to 2015 Progress Status: Completed (coded as: completed from http://hl7.org/fhir/research-study-status)( ) Description: The main purpose of this study is, in combination with data from the Register and Biobank study and follow-up data from the Norwegian Prescription Database, to compare the long-term effects (4-10 years) of surgical and non-surgical treatment of morbid obesity on obesity related comorbidities by studying changes in medicine usage after treatment. Hypotheses 1. Primary hypothesis: As compared to non-surgical treatment, bariatric surgery will be associated with higher rates of remission, and lower rates of new-onset drug treated hypertension during a follow-up period of ≤ 10 years. 2. Secondary hypotheses: Changes in the usage of other drugs, particularly drugs related to obesity related comorbidities, will differ significantly between patients undergoing bariatric surgery or non-surgical treatment during the follow-up period. Condition: morbid obesity Region: Norway (coded as: NO from urn:iso:std:iso:3166) Study Design: Observational research (coded as: SEVCO:01002 from http://hl7.org/fhir/study-design) Study Design: Parallel cohort design (coded as: SEVCO:01011 from http://hl7.org/fhir/study-design) Study Design: Longitudinal data collection (coded as: SEVCO:01028 from http://hl7.org/fhir/study-design) Related Item (specification-of): eAppendix 2. Research Protocol Related Item (derived-from): JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort Associated Party: Jøran Hjelmesæth, Leader of the Morbid Obesity Center, Vestfold Hospital Trust, and Professor at the Department for Endocrinology, Morbid Obesity and Preventitive Medicine, Medical Clinic, the Institute for Clinical Medicine, the University of Oslo. (primary-investigator (coded as: primary-investigator from http://hl7.org/fhir/research-study-party-role); Project Leader and Main Supervisor) Associated Party: Gunn Signe Jakobsen, cand. med. at the Morbid Obesity Center, South-Eastern Norway Regional Health Authority. Doctor with a specialisation at the department for Gastroenterological Surgery, Akershus University Hospital. Mobil: 916 25 647, email: gunn.signe.jakobsen@siv.no (collaborator (coded as: collaborator from http://hl7.org/fhir/research-study-party-role); PhD Candidate) Associated Party: Jens Kristoffer Hertel, PhD, the Morbid Obesity Center, Vestfold Hospital Trust. (collaborator (coded as: collaborator from http://hl7.org/fhir/research-study-party-role); Co-supervisor ) Associated Party: Arild Nesbakken, Professor, the Surgical Clinic, Oslo University Hospital (collaborator (coded as: collaborator from http://hl7.org/fhir/research-study-party-role); Co-supervisor) Associated Party: Rune Sandbu, dr.med, the Morbid Obesity Center and Department of Surgery, Vestfold Hospital Trust. (collaborator (coded as: collaborator from http://hl7.org/fhir/research-study-party-role); Co-supervisor) Associated Party: Milada Cvancarova Småstuen, PhD, the Morbid Obesity Center, South-Eastern Norway Regional Health Authority, Vestfold Hospital Trust (collaborator (coded as: collaborator from http://hl7.org/fhir/research-study-party-role); Biostatistician) Site: Vestfold Hospital Trust Target number of participants: 505 Actual number of participants: 1888 Enrollment Group: StudyGroup: Severely Obese Adults 2018 Norwegian Cohort Comparison Group: Bariatric Surgery () ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort Comparison Group: Medical Obesity Treatment () ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort Objective: Remission of diabetes () OutcomeVariable: Remission of diabetes Objective: New onset depression () OutcomeVariable: New onset depression Objective: Treatment with opioids () OutcomeVariable: Treatment with opioids Objective: Additional GI surgical procedure () OutcomeVariable: Additional GI surgical procedure Result: JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort Result: Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
The Long-Term Effect of Treatment of Morbid Obesity
Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities [Database Entry: FHIR ResearchStudy Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 208285. Revised 2025-05-13. Available at: https://fevir.net/resources/ResearchStudy/208285. Computable resource at: https://fevir.net/resources/ResearchStudy/208285#json.
JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
The main purpose of this study is, in combination with data from the Register and Biobank study and follow-up data from the Norwegian Prescription Database, to compare the long-term effects (4-10 years) of surgical and non-surgical treatment of morbid obesity on obesity related comorbidities by studying changes in medicine usage after treatment. Hypotheses 1. Primary hypothesis: As compared to non-surgical treatment, bariatric surgery will be associated with higher rates of remission, and lower rates of new-onset drug treated hypertension during a follow-up period of ≤ 10 years. 2. Secondary hypotheses: Changes in the usage of other drugs, particularly drugs related to obesity related comorbidities, will differ significantly between patients undergoing bariatric surgery or non-surgical treatment during the follow-up period.
Jøran Hjelmesæth, Leader of the Morbid Obesity Center, Vestfold Hospital Trust, and Professor at the Department for Endocrinology, Morbid Obesity and Preventitive Medicine, Medical Clinic, the Institute for Clinical Medicine, the University of Oslo.
Gunn Signe Jakobsen, cand. med. at the Morbid Obesity Center, South-Eastern Norway Regional Health Authority. Doctor with a specialisation at the department for Gastroenterological Surgery, Akershus University Hospital. Mobil: 916 25 647, email: gunn.signe.jakobsen@siv.no
Jens Kristoffer Hertel, PhD, the Morbid Obesity Center, Vestfold Hospital Trust.
Arild Nesbakken, Professor, the Surgical Clinic, Oslo University Hospital
Rune Sandbu, dr.med, the Morbid Obesity Center and Department of Surgery, Vestfold Hospital Trust.
Milada Cvancarova Småstuen, PhD, the Morbid Obesity Center, South-Eastern Norway Regional Health Authority, Vestfold Hospital Trust
StudyGroup: Severely Obese Adults 2018 Norwegian Cohort
ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort
ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
OutcomeDefinition: Remission of diabetes
OutcomeDefinition: Treatment with opioids
OutcomeDefinition: Additional GI surgical procedure
Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)